Indivior Pharmaceuticals, Inc.INDVEarnings & Financial Report
Nasdaq
Indivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market.
NextMar 13, 2026
INDV Q3 2026 Key Financial Metrics
营收
$314.0M
毛利润
$230.0M
营业利润
$43.0M
净利润
$42.0M
毛利率
73.2%
营业利润率
13.7%
净利率
13.4%
同比增长
N/A
EPS
$0.33
资金流向
Indivior Pharmaceuticals, Inc. Q3 2026 Financial Summary
Indivior Pharmaceuticals, Inc. reported revenue of $314.0M for Q3 2026, with a net profit of $42.0M (13.4% margin). Cost of goods sold was $84.0M, operating expenses totaled $187.0M.
Key Financial Metrics
| Total Revenue | $314.0M |
|---|---|
| Net Profit | $42.0M |
| Gross Margin | 73.2% |
| Operating Margin | 13.7% |
| Report Period | Q3 2026 |
利润表
| Q1 2024 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|
| 营收 | $284.0M | $266.0M | $302.0M | $314.0M |
| 同比增长 | N/A | N/A | N/A | N/A |
资产负债表
| Q1 2024 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|
| 总资产 | N/A | $1.38B | $1.45B | $1.42B |
| 总负债 | N/A | $1.66B | $1.71B | $1.62B |
| 股东权益 | $-161.0M | $-285.0M | $-257.0M | $-207.0M |
现金流量表
| Q1 2024 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|
| 经营性现金流 | $-37.0M | $75.0M | $158.0M | $-39.0M |